Bayer has signed a collaboration and services agreement with CureVac to support the continued development, supply, and operation of CureVac’s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its expertise and infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance, and support in selected countries.
Based on the collaboration agreement, CureVac will be the Marketing Authorization Holder for the product, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets. Bayer holds further options to become Marketing Authorization Holder in other markets outside of Europe.
Since November 2020, CureVac has been expanding its partner network for the development, production, and distribution of its vaccine candidate, and will work with Wacker and Fareva, among others. In December 2020, the company started its global pivotal Phase 2b/3.
Also of Interest
- Collection: SARS-CoV-2 Virus
What we know about the new coronavirus and COVID-19 - Clever Picture: Searching for a Vaccine
